U.S., Sept. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07844551) titled 'ImmunoADC Therapy for Induction Conversion in Patients With Stage IVB OSCC/OPSCC' on Sept. 22.
Brief Summary: To evaluate the efficacy and safety of Becotatug Vedotin (EGFR-targeted ADC, MRG003) plus Pucotenlimab (PD-1 inhibitor), compared with platinum-based chemotherapy/chemoradiotherapy, as an induction conversion regimen for downstaging primary stage IVB oral squamous cell carcinoma or HPV16-negative oropharyngeal squamous cell carcinoma.
Study Start Date: Oct. 20
Study Type: INTERVENTIONAL
Condition:
Stage IVB Oral Cavity Squamous Cell Carcinoma
Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Intervention:
DRUG:...